ISRCTN ISRCTN53517394
DOI https://doi.org/10.1186/ISRCTN53517394
Secondary identifying numbers N/A
Submission date
22/06/2006
Registration date
26/07/2006
Last edited
15/08/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Prof Falk Leichsenring
Scientific

von Sieboldstrasse 5
Goettingen
37075
Germany

Phone +49 (0)55 15005278
Email Fleichs@gwdg.de

Study information

Study designRandomized controlled multicenter trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleThe social phobia psychotherapy research network
Study acronymSOPHO-NET
Study hypothesisDifferential efficacy of short-term psychodynamic psychotherapy (STPP) and cognitive-behavioral therapy (CBT) in social phobia therapy - named hypothesis A1

The first add-on study (named C1) of this multicentre trial will be studying genetic polymorphisms in patients with social phobia who are treated with STPP and CBT.

The second add-on study (named C2) of this multicentre trial will be studying the neural functional and structural changes in patients with social phobia who are treated with STPP and CBT.

The third add-on study (named C3) of this multicentre trial will be studying the attachment characteristics as differential predictors of treatment outcome in 128 patients with social phobia who are treated with STPP and CBT.
Ethics approval(s)Ethics Committee of the Medical Faculty of the University of Goettingen, 06/12/2006
ConditionSocial phobia (social anxiety disorder)
InterventionManualized short-term psychodynamic psychotherapy (STPP) versus manualized cognitive-behavioral therapy (CBT)
Intervention typeOther
Primary outcome measureFor A1, primary outcome is no diagnosis of SP according to the SCID-I DSM-IV and the Liebowitz Social Anxiety Scale

For C1, the primary outcome will be, that the psychotherapy outcome is associated with genetic variation in the serotonin transporter (SERT) gene (directed: L12 higher pre-post difference in the Liebowitz Social Anxiety Scale [LSAS])

For C2, primary outcomes will include normalisation of neural structural and functional abnormalities after successful treatment

For C3, primary outcomes will be whether patients reveal a secure organized attachment; representation will reach a better outcome than those with insecure features and\or disorganized states of mind
Secondary outcome measuresFor A1, secondary outcomes will include:
1. Social anxiety (Social Phobia and Anxiety Inventory [SPAI])
2. Depression (Beck Depression Inventory [BDI])
3. Interpersonal problems (IIP)
4. Self-image
5. Quality of life or social functioning (short-form-12 questionnaire [SF-12])
6. Costs and utilities of the treatments

For C1, the secondary outcome will be, that the severity of social phobia is linked with genetic variation in SERT gene (directed: S10 higher LSAS at baseline)

For C2 secondary outcome will include specificity of neural structural and functional abnormalities in social phobia

For C3, secondary outcome will include whether a self-reported attachment will significantly change after successful therapy indicating increased security. This will be tested by using the Experiences in Close Relationships-Revised (ECR-R) instrument within the entire sample (n = 512)
Overall study start date01/10/2006
Overall study end date01/10/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants512
Participant inclusion criteria1. Diagnosis of social phobia (SP) according to the Structured Interview for Diagnostic and Statistical Manual of Mental Disorders - fourth edition [SCID-I DSM-IV]) and primary diagnosis of social phobia according to the Liebowitz Social Anxiety Scale >302
2. Aged 18 to 59 versus 60 to 70 years
4. Participants must be made up of 60% women; 40% men
Participant exclusion criteria1. Psychotic disorder
2. Risk of self-harm
3. Acute substance related disorder
4. Personality disorders except for cluster C
5. Organic mental disorder
6. Severe medical conditions
7. Concurrent psychotherapeutic or psychopharmacological treatment
Recruitment start date01/10/2006
Recruitment end date01/10/2009

Locations

Countries of recruitment

  • Germany

Study participating centre

von Sieboldstrasse 5
Goettingen
37075
Germany

Sponsor information

Ministry for Development and Research (Bundesministerium für Bildung und Forschung [BMBF]) (Germany)
Government

Hannoversche Strasse 28-30
Berlin
10115 Berlin
Germany

Phone +49 (0)18 88570
Email Detlef.Boecking@dlr.de
Website http://www.bmbf.de
ROR logo "ROR" https://ror.org/04pz7b180

Funders

Funder type

Government

Bundesministerium für Bildung und Forschung
Government organisation / National government
Alternative name(s)
Federal Ministry of Education and Research, BMBF
Location
Germany

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 23/12/2013 Yes No
Results article results 19/01/2016 Yes No

Editorial Notes

15/08/2016: Publication reference added.